Merimepodib (VX-497): Selective Oral IMPDH Inhibitor for Antiviral, Cancer, and Immunology Research

Executive Summary: Merimepodib (VX-497) is a potent, noncompetitive, orally bioavailable inhibitor of inosine monophosphate dehydrogenase (IMPDH), essential for guanine nucleotide biosynthesis in proliferating cells [APExBIO]. It demonstrates broad-spectrum antiviral activity, including against hepatitis B virus (HBV), human cytomegalovirus (HCMV), and porcine epidemic diarrhea virus (PEDV), by depleting guanine nucleotide pools [Zhou et al. 2026]. In vitro, Merimepodib inhibits lymphocyte proliferation at nanomolar concentrations, and its specificity for IMPDH is confirmed by guanosine rescue [Internal]. In vivo, it suppresses IgM antibody responses and prolongs skin graft survival in mice, validating its immunosuppressive efficacy. Merimepodib is soluble in DMSO (≥45.2 mg/mL), but insoluble in ethanol or water, and should be stored at -20°C as a solid for stability [APExBIO].

Biological Rationale

Guanine nucleotides are critical for DNA and RNA synthesis, cell proliferation, and viral replication [Zhou et al. 2026]. The IMPDH enzyme catalyzes the conversion of inosine monophosphate (IMP) to xanthosine monophosphate (XMP), a rate-limiting step in de novo guanine nucleotide biosynthesis. Viruses such as PEDV, HBV, and HCMV hijack host nucleotide synthesis to support their replication. Targeting IMPDH provides a host-directed strategy for antiviral and anticancer interventions [Internal]. Merimepodib, developed by APExBIO as product B1112, enables selective inhibition of the IMPDH pathway, disrupting nucleotide metabolism in both cancer and viral infection models. This expands upon the mechanistic overview provided by this article by detailing recent in vitro and in vivo findings.

Mechanism of Action of Merimepodib (VX-497)

Merimepodib acts as a noncompetitive inhibitor of IMPDH, preventing the conversion of IMP to XMP [APExBIO]. This step is essential for guanine nucleotide biosynthesis. Inhibition leads to depletion of GTP pools, resulting in cell cycle arrest and impaired nucleic acid synthesis. The antiproliferative effects of Merimepodib are reversible with exogenous guanosine supplementation, confirming on-target IMPDH inhibition [Internal]. Viruses dependent on high guanine nucleotide flux, such as HBV and PEDV, are especially susceptible to IMPDH inhibition. Merimepodib is orally bioavailable and demonstrates activity in both in vitro and animal models.

Evidence & Benchmarks

• Merimepodib inhibits primary human, rat, mouse, and dog lymphocyte proliferation at ~100 nM concentrations; effect is reversed by exogenous guanosine (Zhou et al. 2026, ASM J Virol).
• Oral Merimepodib suppresses IgM antibody response and prolongs skin graft survival in mice, indicating dose-dependent immunosuppression (APExBIO, product page).
• Shows potent antiviral activity against HBV, HCMV, EMCV, and RSV with IC50 values of 0.38–1.14 μM in cell-based assays (APExBIO, product page).
• In PEDV-infected LLC-PK1 and Vero E6 cells, Merimepodib reduces viral RNA levels and viral titers (Zhou et al. 2026, ASM J Virol).
• IMPDH inhibition via Merimepodib reduces synthesis of guanine nucleotides, impairing both cell proliferation and viral replication (Zhou et al. 2026, ASM J Virol).

For an updated synthesis incorporating these benchmarks within translational workflows, see Translational Leverage through IMPDH Pathway Inhibition, which this article extends by highlighting novel evidence on viral metabolic hijacking.

Applications, Limits & Misconceptions

Merimepodib is widely used in:

• Cancer chemotherapy research: Disrupts nucleotide biosynthesis in rapidly dividing tumor cells [Internal].
• Immunology: Inhibits lymphocyte proliferation and modulates immune responses.
• Antiviral research: Demonstrates efficacy against HBV, HCMV, RSV, EMCV, PEDV, and has been tested in HCV, Zika, Ebola, and FMDV models [Zhou et al. 2026].

This article clarifies and expands on Merimepodib (VX-497): IMPDH Inhibitor for Cancer and Anti... by detailing quantitative benchmarks and specificity data.

Common Pitfalls or Misconceptions

• Merimepodib is not effective against viruses or cell types that do not rely on de novo guanine nucleotide biosynthesis.
• The compound is not recommended for diagnostic or therapeutic use in humans; research use only per APExBIO guidelines.
• Solubility is high in DMSO but poor in ethanol and water; inappropriate solvent use can compromise experimental validity.
• Long-term storage in solution is not recommended; stability is preserved as a solid at -20°C.
• Guanosine supplementation reverses Merimepodib’s effects, which can confound specificity controls if not properly managed.

Workflow Integration & Parameters

Merimepodib (B1112) is supplied as a solid by APExBIO and should be stored at -20°C. For cell-based assays, dissolve in DMSO to a stock concentration of ≥45.2 mg/mL. Working concentrations in vitro typically range from 100 nM to 1 μM, depending on cell type and endpoint. For in vivo studies, oral dosing is supported by pharmacokinetic data. Shipping uses blue ice for stability. The compound is validated in lymphocyte proliferation assays, viral replication assays, and immune response modulation workflows. For specific integration steps and troubleshooting, researchers may refer to this protocol article, which this review updates by providing the latest in vitro and in vivo dosing benchmarks.

Conclusion & Outlook

Merimepodib (VX-497) is a rigorously characterized, selective, and orally bioavailable IMPDH inhibitor with broad applications in cancer, immunology, and antiviral research. By targeting the IMPDH-dependent guanine nucleotide biosynthesis pathway, it offers a robust method for dissecting cellular proliferation and viral replication mechanisms. The product is distributed by APExBIO and is intended for research use only. Ongoing studies continue to define its translational potential and limitations, reinforcing its value as a gold-standard tool for IMPDH pathway interrogation.